Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have a reliable hypoglycaemic and weight-loss effect that can intervene in obesity, which is the basis of type 2 diabetes pathology
What real-world retatrutide results might look like Since retatrutide is not yet commercially available, we cannot assess real-world performance
Similar to managing high blood pressure or cholesterol, GLP-1 medications are often part of a lifelong approach to care for chronic conditions, as discussed in long-term therapy research
Slower gastric emptying helps blunt post-meal glucose spikes and can prolong feelings of fullness after eating
Food and Drug Administration (FDA) for obesity management, have shown efficacy not only in weight reduction but also in improving metabolic 10,11,12,13,14,15 and cardiovascular outcomes 16
M.KirschenbaumD